We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+2.97%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$1.72B
AUM Growth
-$344M
Cap. Flow
-$310M
Cap. Flow %
-18%
Top 10 Hldgs %
22.96%
Holding
279
New
14
Increased
72
Reduced
169
Closed
14

Sector Composition

Rank Sector Weight
1 Technology 27.05%
2 Healthcare 26.07%
3 Industrials 15.04%
4 Consumer Discretionary 11.17%
5 Communication Services 6.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UMPQ
76
DELISTED
Umpqua Holdings Corp
UMPQ
$5.33M 0.31%
311,943
-2,616
-0.8% -$46.5K
CHUY
77
DELISTED
Chuy's Holdings, Inc. Common Stock
CHUY
$5.33M 0.31%
229,769
+1,121
+0.5% +$25K
STAA icon
78
STAAR Surgical
STAA
$1.25B
$5.23M 0.3%
74,077
+6,290
+9% +$538K
ICFI icon
79
ICF International
ICFI
$1.67B
$5.21M 0.3%
47,773
-418
-0.9% -$42K
FN icon
80
Fabrinet
FN
$19.2B
$5.12M 0.3%
53,626
-1,029
-2% -$99.1K
ERII icon
81
Energy Recovery
ERII
$418M
$5.1M 0.3%
234,479
+488
+0.2% +$11K
DEN
82
DELISTED
Denbury Inc.
DEN
$5.09M 0.3%
59,044
-510
-0.9% -$39.1K
GATX icon
83
GATX Corp
GATX
$6.24B
$5M 0.29%
58,663
+7,859
+15% +$757K
KPTI icon
84
Karyopharm Therapeutics
KPTI
$44.2M
$4.96M 0.29%
60,606
-27,116
-31% -$2.03M
AIN icon
85
Albany International
AIN
$1.74B
$4.93M 0.29%
62,486
-820
-1% -$70.5K
FATE icon
86
Fate Therapeutics
FATE
$325M
$4.91M 0.28%
219,146
-53,887
-20% -$1.56M
PTC icon
87
PTC
PTC
$16.5B
$4.89M 0.28%
46,792
-64,554
-58% -$7.37M
MATV icon
88
Mativ Holdings
MATV
$690M
$4.89M 0.28%
221,365
+1,458
+0.7% +$33.4K
MSM icon
89
MSC Industrial Direct
MSM
$6.83B
$4.79M 0.28%
65,754
-19,913
-23% -$1.57M
HURN icon
90
Huron Consulting
HURN
$2.44B
$4.74M 0.27%
71,495
+151
+0.2% +$10K
HRMY icon
91
Harmony Biosciences
HRMY
$2.28B
$4.7M 0.27%
106,127
-1,411
-1% -$68.8K
OR icon
92
OR Royalties Inc
OR
$6.25B
$4.62M 0.27%
453,556
-2,055
-0.5% -$20.6K
QCRH icon
93
QCR Holdings
QCRH
$1.69B
$4.61M 0.27%
90,489
+189
+0.2% +$10.6K
RMBS icon
94
Rambus
RMBS
$10.7B
$4.59M 0.27%
180,578
+90,365
+100% +$2.26M
PWSC
95
DELISTED
PowerSchool Holdings, Inc.
PWSC
$4.57M 0.26%
273,607
+120,566
+79% +$1.95M
CLNE icon
96
Clean Energy Fuels
CLNE
$346M
$4.56M 0.26%
+853,370
New +$5.35M
ABST
97
DELISTED
Absolute Software Corp
ABST
$4.51M 0.26%
388,266
+919
+0.2% +$9.36K
DCGO icon
98
DocGo
DCGO
$57.8M
$4.45M 0.26%
448,533
+43,786
+11% +$395K
CBZ icon
99
CBIZ
CBZ
$2.96B
$4.43M 0.26%
103,622
+30
+0% +$1.31K
GXO icon
100
GXO Logistics
GXO
$5.45B
$4.34M 0.25%
123,902
-37,010
-23% -$1.63M

Similar funds

Rice Hall James & Associates's Q3 2022 Portfolio in Review

As of Q3 2022, Rice Hall James & Associates held 279 positions worth $1.72B, down 17% from $2.07B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Rice Hall James & Associates withdrew a net $310M in Q3 2022, closing 14 positions and reducing 169 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $7.39M position sold in full.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in TechTarget worth $8.44M.

  • Rice Hall James & Associates's largest Q3 2022 buy was TechTarget: 142,597 shares worth $8.44M.
  • Rice Hall James & Associates added most to Upland Software in Q3 2022, an estimated $3.67M increase.
  • Rice Hall James & Associates's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $26.8M.
  • Rice Hall James & Associates fully exited Global Blood Therapeutics, Inc. in Q3 2022, selling an estimated $7.39M.
  • Rice Hall James & Associates's ten largest holdings make up 23% of its $1.72B portfolio in Q3 2022.
  • Rice Hall James & Associates opened 14 new positions and closed 14 in Q3 2022.
  • Rice Hall James & Associates's portfolio value fell 17% quarter-over-quarter to $1.72B.

Based on Rice Hall James & Associates's 13F filing for Q3 2022, filed 1 Nov 2022.